Medicine: Go-Ahead for A Wonder Drug

After months of controversy, the Food and Drug Administration last week ended its ambivalent attitude toward a genetically engineered drug that dissolves blood clots. FDA Commissioner Frank Young announced that the agency had approved the use of tissue plasminogen activator, or t-PA, as an emergency treatment for heart attacks. The drug activates an enzyme that destroys fibrin, the protein that binds clots together. Arterial clotting is thought to be a factor in most of the 1.5 million heart attacks suffered annually in the U.S., so t-PA could save thousands of lives. With an injection of the drug, said Young, "the odds...

Want the full story?

Subscribe Now

Subscribe
Subscribe

Get TIME the way you want it

  • One Week Digital Pass — $4.99
  • Monthly Pay-As-You-Go DIGITAL ACCESS$2.99
  • One Year ALL ACCESSJust $30!   Best Deal!
    Print Magazine + Digital Edition + Subscriber-only Content on TIME.com

Learn more about the benefits of being a TIME subscriber

If you are already a subscriber sign up — registration is free!